-
The opioid crisis in the United States has killed more than 200,000 people. Behind this, the fingers point to the pharmaceutical giant Purdue Pharma
-
For many years, the United States has been facing a serious health crisis due to the opioid addiction epidemic. Over the last twenty years, the prescription of opioids has grown considerably, perhaps driven by pharmaceutical companies.
-
How new therapy options can be obtained from the complex pathophysiology of allergies was also the subject of EAACI 2019 in Lisbon.
-
Epigenetic changes to the genome affect cellular gene activity. Does epigenetics form the interface between environmental factors and asthmatic diseases?
-
The World Environment Day, a United Nations event, focuses this year on air pollution, an environmental problem that kills some 7 million people every year worldwide.
-
From 1 to 5 June 2019 the EAACI Congress greeted once again with a "Welcome to Lisbon"! This year's event centered primarily on precision medicine; with many innovative concepts and ideas on the future of allergology throughout the congress' numerous sessions.
-
At the end of this year's Congress of the American Society of Oncology (ASCO) in Chicago, results of the primary endpoint analysis of the CLL14 study were presented for the first time. These are results that will change current medical approaches.
-
The PD-1 inhibitor pembrolizumab (Keytruda) significantly improves the 5-year survival rates of patients with non-small cell lung cancer (NSCLC). The effect was particularly good in patients with high PD-L1 expression.
-
The non-steroidal antiandrogen ensalutamide plus standard therapy increased the 3-year survival rate in men with mHSPC to 80% compared to 72% achieved with other non-steroidal antiandrogens. This was confirmed by an interim analysis of the phase III ENZAMET study.
-
In about 50% of metastasized melanomas, a BRAF mutation is found, in these cases, targeted therapy can be applied. But immunotherapeutics have also revolutionized melanoma treatment in the last ten years.
-
For the first time, a biomarker-based therapy prolonged overall survival in premenopausal women with breast cancer. In the MONALEESA 7 Phase III study, a joint Ribociclib/endocrine therapy reduced death risk by 29%.
-
Anal carcinoma is closely associated with infection by human papillomaviruses. An HPV vaccination, therefore, offers a good possibility for prevention.
-
There are many reasons for physicians to become involved in social media, and various studies have now also proven the benefits. Nonetheless, risks must also be taken into account, as we learned at ASCO 2019.
-
The lowest dose of oxaliplatin/capecitabine tested was as effective in elderly and frail patients with advanced gastroesophageal carcinoma as the highest dose investigated.
-
CAR-T cell therapy is highly controversial in research. The two most important side effects, cytokine release syndrome, and neurotoxicities were presented and discussed in a symposium.
-
Cancer-specific DNA repair defects are common in malignant tissue, but they provide an opportunity for therapeutic attack.
-
For the first time, a biomarker-based therapeutic approach in pancreatic cancer has been able to prolong progression-free survival (PFS).
-
The European Academy of Andrology (EAA) has issued a new guideline with 15 recommendations for managing these clinical cases.
-
A recent study on mice concludes that targeted ultrasound could be an effective, noninvasive and drug-free way to increase insulin levels in people with type 2 diabetes.
-
For osteoporosis, there is still a lot of catching up needed throughout Europe: some 85% of women with osteoporosis-related bone fractures do not receive adequate treatment to prevent the recurrence of such fractures.
